Advertisement
U.S. markets closed
  • S&P Futures

    5,209.00
    -5.75 (-0.11%)
     
  • Dow Futures

    39,205.00
    -18.00 (-0.05%)
     
  • Nasdaq Futures

    18,189.00
    -42.50 (-0.23%)
     
  • Russell 2000 Futures

    2,047.70
    -2.10 (-0.10%)
     
  • Crude Oil

    82.58
    -0.14 (-0.17%)
     
  • Gold

    2,164.60
    +0.30 (+0.01%)
     
  • Silver

    25.33
    +0.07 (+0.26%)
     
  • EUR/USD

    1.0878
    +0.0001 (+0.01%)
     
  • 10-Yr Bond

    4.3400
    +0.0360 (+0.84%)
     
  • Vix

    14.33
    -0.08 (-0.56%)
     
  • GBP/USD

    1.2723
    -0.0005 (-0.04%)
     
  • USD/JPY

    149.3870
    +0.2890 (+0.19%)
     
  • Bitcoin USD

    65,219.95
    -2,749.95 (-4.05%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,722.55
    -4.87 (-0.06%)
     
  • Nikkei 225

    39,596.29
    -144.15 (-0.36%)
     

Today's Research Reports on Stocks to Watch: Genocea Biosciences and Corbus Pharmaceuticals

NEW YORK, NY / ACCESSWIRE / August 11, 2017 / It was a rough day for Massachusetts-based biotech companies Genocea Biosciences and Corbus Pharmaceuticals. Both stocks saw losses after posting disappointing second quarter results earlier this week.

RDI Initiates Coverage on:

Genocea Biosciences, Inc.
https://ub.rdinvesting.com/news/?ticker=GNCA

Corbus Pharmaceuticals Holdings, Inc.
https://ub.rdinvesting.com/news/?ticker=CRBP

Genocea Biosciences, Inc.'s shares closed down 7.42% on Thursday with a little over 600,000 shares traded. The company reported second quarter financial results this week and reported a loss of $15.4 million. On a per share basis, this was a loss of 54 cents. Wall Street had been expecting a loss of just 46 cents. The company is developing GEN-003, an investigational immunotherapy for the treatment of genital herpes. The company is also applying its unique and proprietary T cell antigen identification platform, ATLAS™, to immuno-oncology and cancer vaccine development. The company stated, "With respect to our cancer vaccine program, recent scientific publications on neoantigen cancer vaccines suggest that the concept has promise, but we think that there is significant room for improvement. We believe that Genocea's ATLAS platform can enable better neoantigen selection and that, combined with our vaccinology expertise, positions us strongly in this emerging field. We expect to file an IND by the end of 2017 for our neoantigen vaccine, GEN-009, and we are also continuing our preclinical work on common antigen cancer vaccines and an EBV-related cancer vaccine."

Access RDI's Genocea Biosciences, Inc. Research Report at:
https://ub.rdinvesting.com/news/?ticker=GNCA

Corbus Pharmaceuticals Holdings, Inc.'s shares sank into the red yesterday, closing the day down 3.31%. Though there was no significant news yesterday, traders were still feeling discouraged by the Massachusetts-based company's second quarter financial results. The company reported a loss of $7.3 million in the period. On a per share basis, this was a loss of 15 cents. Revenue adjusted was $350,000. The clinical stage drug development company that targets rare, chronic, serious inflammatory and fibrotic diseases, also announced that it plans to commence a Phase 3 study of anabasum for the treatment of systemic sclerosis in the fourth quarter of 2017. Anabasum is a novel synthetic oral endocannabinoid-mimetic drug that is designed to resolve chronic inflammation and halt fibrosis. CEO Yuval Cohen, Ph.D., commented, "We have made significant progress on the corporate, operational and clinical fronts, enabling the Company to move forward with a strong balance sheet and plans to execute on multiple potentially impactful milestones coming up in the second half of this year." Since the start of the year, shares of Corbus have fallen over 30%.

Access RDI's Corbus Pharmaceuticals Holdings, Inc. Research Report at:
https://ub.rdinvesting.com/news/?ticker=CRBP

Our Actionable Research on Genocea Biosciences, Inc. (NASDAQ: GNCA) and Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

Advertisement